PPHM News $PPHM
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 4 mins ago
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 8 cents per share in the first quarter of fiscal 2015.
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwire - Tue Sep 09, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an update on its advancing clinical pipeline led by its investigational immuno-oncology candidate bavituximab and reviewed other corporate developments.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Mon Sep 08, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Marketwire - Tue Sep 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on September 9, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
Stock to Watch: Peregrine Pharmaceuticals Up 8.1% (PPHM)
Comtex SmarTrend(R) - Mon Aug 11, 1:19PM CDT
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's best performing low-priced stocks, up 8.1% to $1.73 on 1.1x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.4%) and outperformed the S&P 500 (8.1% to the S&P's 0.6%) during today's trading.
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Marketwire - Mon Aug 11, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at 12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Mon Jul 14, 3:01PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Peregrine Earnings Today: 3 Questions That Need Answers
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 1:01PM CDT
Peregrine Pharmaceuticals will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may...
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
5 Stocks to Watch This Week
Rick Munarriz, The Motley Fool - Motley Fool - Sat Jul 12, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday Peregrine Pharmaceuticals kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is...
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Marketwire - Mon Jul 07, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
PR Newswire - Mon Jun 30, 5:40AM CDT
On Friday, June 27, 2014, the NASDAQ Composite ended at 4,397.93, up 0.43%, the Dow Jones Industrial Average edged 0.03% higher, to finish the day at 16,851.84, and the S&P 500 closed at 1,960.96, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.06, down 0.21%, while the index has advanced 4.44% in the previous three months. Investor-Edge has initiated coverage on the following equities: Insmed Inc. (NASDAQ: INSM), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), CytRx Corp. (NASDAQ: CYTR) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free technical research on INSM, PPHM, CYTR and CLDX can be downloaded upon signing up at:
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Investors look to Lighten Up on Shares of Peregrine Pharmaceuticals, Shares Down 9.8% (PPHM)
Comtex SmarTrend(R) - Mon Mar 24, 11:43AM CDT
Peregrine Pharmaceuticals (NASDAQPHM) is one of today's worst performing low-priced stocks, down 9.8% to $2.02 on 1.0x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 5.3 million shares, vs. average volume of 5.3 million shares per day. The stock has underperformed the Dow (-9.8% to the Dow's -0.5%) and underperformed the S&P 500 (-9.8% to the S&P's -0.8%) during today's trading.
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:39AM CDT
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue?
Galena Biopharma vs. Peregrine Pharmaceuticals: Which is the Better Buy?
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 11:05AM CDT
For more than a year now you'd have difficulty finding a sector that has performed better on the market than health care. From Big Pharma down to medical device makers and small biotechs, health care has absolutely been on a tear. As such, it's been...
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 4 mins ago
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 8 cents per share in the first quarter of fiscal 2015.
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwire - Tue Sep 09, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an update on its advancing clinical pipeline led by its investigational immuno-oncology candidate bavituximab and reviewed other corporate developments.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Mon Sep 08, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
. Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Marketwire - Tue Sep 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on September 9, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
Stock to Watch: Peregrine Pharmaceuticals Up 8.1% (PPHM)
Comtex SmarTrend(R) - Mon Aug 11, 1:19PM CDT
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's best performing low-priced stocks, up 8.1% to $1.73 on 1.1x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.4%) and outperformed the S&P 500 (8.1% to the S&P's 0.6%) during today's trading. Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Marketwire - Mon Aug 11, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at 12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Mon Jul 14, 3:01PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Peregrine Earnings Today: 3 Questions That Need Answers
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 1:01PM CDT
Peregrine Pharmaceuticals will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may...
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
5 Stocks to Watch This Week
Rick Munarriz, The Motley Fool - Motley Fool - Sat Jul 12, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday Peregrine Pharmaceuticals kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is...
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Marketwire - Mon Jul 07, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
PR Newswire - Mon Jun 30, 5:40AM CDT
On Friday, June 27, 2014, the NASDAQ Composite ended at 4,397.93, up 0.43%, the Dow Jones Industrial Average edged 0.03% higher, to finish the day at 16,851.84, and the S&P 500 closed at 1,960.96, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.06, down 0.21%, while the index has advanced 4.44% in the previous three months. Investor-Edge has initiated coverage on the following equities: Insmed Inc. (NASDAQ: INSM), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), CytRx Corp. (NASDAQ: CYTR) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free technical research on INSM, PPHM, CYTR and CLDX can be downloaded upon signing up at:
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Investors look to Lighten Up on Shares of Peregrine Pharmaceuticals, Shares Down 9.8% (PPHM)
Comtex SmarTrend(R) - Mon Mar 24, 11:43AM CDT
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's worst performing low-priced stocks, down 9.8% to $2.02 on 1.0x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 5.3 million shares, vs. average volume of 5.3 million shares per day. The stock has underperformed the Dow (-9.8% to the Dow's -0.5%) and underperformed the S&P 500 (-9.8% to the S&P's -0.8%) during today's trading. Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:39AM CDT
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue?
Galena Biopharma vs. Peregrine Pharmaceuticals: Which is the Better Buy?
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 11:05AM CDT
For more than a year now you'd have difficulty finding a sector that has performed better on the market than health care. From Big Pharma down to medical device makers and small biotechs, health care has absolutely been on a tear. As such, it's been...
